Skip to main content
Sports Medicine - Open
Fig. 4 | Sports Medicine - Open

Fig. 4

From: Acute Effects of Single Versus Combined Inhaled β2-Agonists Salbutamol and Formoterol on Time Trial Performance, Lung Function, Metabolic and Endocrine Variables

Fig. 4

A Time trial performance represented by average power output and B selected lung function variables (differences) by treatment with salbutamol (SAL), formoterol (FOR), salbutamol + formoterol (SAL + FOR) as well as placebo (PLA) during the 10-min-long time trial test. No performance-enhancing effect was observed for all medications in the average power output for males or females. Lung function variables—represented by FEV1 (volume that has been exhaled at the end of the first second of forced expiration), MEF25 (Mean expiratory flow) and sRaw (specific resistance of the airways)—significantly improved for all β2-agonist combinations compared to PLA. Data are presented as mean ± standard error for average power output. ***p ≤ 0.001 versus PLA

Back to article page